Abnormalities in the distributed network of sustained attention predict neuroleptic treatment response in schizophrenia

Neuropsychopharmacology

Volumn 19, Issue 1, 1998, Pages 36-47

  Cohen, Robert M ^a   Nordahl, Thomas E ^a   Semple, William E ^a   Andreason, Paul ^a   Pickar, David ^a  

^a Section on Clinical Brain Imaging   (United States)

Author keywords

Cerebral metabolic rates; Deoxyglucose; Frontal cortex; Positron emission tomography; Striatum; Thalamus

Indexed keywords

FLUORODEOXYGLUCOSE F 18; NEUROLEPTIC AGENT;

ADULT; ARTICLE; ATTENTION; BRAIN METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; FRONTAL CORTEX; GLUCOSE METABOLISM; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; SCHIZOPHRENIA; THALAMUS; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; ATTENTION; AUDITORY PERCEPTION; BASAL GANGLIA; DRUG RESISTANCE; HIPPOCAMPUS; HUMANS; MALE; NERVE NET; PREFRONTAL CORTEX; PROGNOSIS; REGRESSION ANALYSIS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; THALAMUS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0031780389     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(97)00201-7     Document Type: Article

References (44)

1. Andreasen NC Scale for the Assessment of Negative Symptoms (SANS). 1984;University of Iowa, Iowa City.
2. Andreason PJ, Zametkin AJ, Guo AC, Baldwin P, Cohen RM Gender related differences in regional cerebral glucose metabolism in normal volunteers. Psychiatr Res. 51:1994;175-183.
3. Biver F, Goldman S, Luxen A, Delvenne B, De Maertelaer V, De La Fuente J, Mendelwicz J, Lostra F Altered frontostriatal relationship in unmedicated schizophrenic patients. Psychiatry Res. 61:1995;161-171.
4. Brooks RA Alternative formula for glucose utilization using labeled deoxyglucose. J Nucl Med. 23:1982;538-539.
5. Buchsbaum MS, Nuechterlein KH, Haier RJ, Wu J, Sicotte N, Hazlett E, Asarnow R, Potkin S, Guich S, Lagunas-Solar M Glucose metabolic rate in normals and schizophrenics during the continuous performance test assessed by positron emission tomography. Br J Psychiatr. 156:1990;216-227.
6. Buchsbaum MS, Haier RJ, Potkin SG, Neuchterlein K, Bracha S, Jerabek P, Trenary J, Tafalla R, Reynolds C, Bunney WE Frontostriatal disorder of cerebral metabolism in never-medicated schizophrenics. Arch Gen Psychiatr. 49:1992;935-942.
7. Buchsbaum MS, Potkin SG, Marshall JF, Lotterberg S, Teng C, Heh C, Tafalla R, Reynolds C, Abel L, Plon L, Bunney WE Effects of clozapine and thiothixene on glucose metabolic rate in schizophrenia. Neuropsychopharmacology. 6:1992;155-163.
8. Buchsbaum MS, Potkin SG, Siegel BV, Lohr J, Katz M, Gottschalk LA, Gulasekaram B, Marshall JF, Lottenberg S, Teng CY, Abel L, Plon L, Bunney WE Striatal metabolic rate and clinical response to neuroleptics in schizophrenia. Arch Gen Psychiatr. 49:1992;966-974.
9. Buchsbaum MS Positron emission tomography studies of abnormal glucose metabolism in schizophrenic illness. Clin Neurosci. 3:1995;122-130.
10. Bunney WE Jr., Hamburg DA Methods for reliable longitudinal observation of behavior. Arch Gen Psychiatr. 9:1963;280-294.
11. Clark C, Carson R, Kessler R, Margolin R, Buchsbaum M, DeLisi L, King C, Cohen R Alternative statistical models for the examination of clinical positron emission tomography/fluorodeoxyglucose data. J Cereb Blood Flow Metab. 5:1984;142-150.
12. Cohen RM, Semple WE, Gros M Positron emission tomography. Psychiatric Clin North Am. 9:1986;65-79.
13. Cohen RM, Semple WE, Gross M, Nordahl TE, DeLisi LE, Holcomb HH, King AC, Morihisa JM, Pickar D Dysfunction in a prefrontal substrate of sustained attention in schizophrenia. Life Sci. 40:1987;2031-2039.
14. Cohen RM, Semple WE, Gross M, Nordahl TE From syndrome to illness. Delineating the pathophysiology of schizophrenia with PET Schizophr Bull. 14:1988;169-176.
15. Cohen RM, Semple WE, Gross M, Nordahl TE, Holcomb HH, Dowling MS, Pickar D The effect of neuroleptics on dysfunction in a prefrontal substrate of sustained attention in schizophrenia. Life Sci. 43:1988;1141-1150.
16. Cohen RM, Semple WE, Gros M, Holcomb HH, Dowling MS, Nordahl TE Functional localization of sustained attention. Comparison to sensory stimulation in the absence of instruction Neuropsychiatr Neuropsychol Behav Neurol. 1:1988;3-20.
17. Cohen RM, Semple WE, Gross M, King AC, Nordahl TE The metabolic brain pattern of sustained auditory discrimination. Exp Brain Res. 92:1992;165-172.
18. Cohen RM, Gross M, Semple WE, Nordahl TE, Sunderland T The metabolic brain pattern of young subjects given scopolamine. Exp Brain Res. 100:1994;133-143.
19. Cohen RM, Nordahl TE, Semple WE, Andreason P, Litman RE, Pickar D The brain metabolic patterns of clozapine- and fluphenazine-treated schizophrenic patients during a continuous performance task. Arch Gen Psychiatr. 54:1997;481-486.
20. DeLisi LE, Holcomb HH, R.M C, Pickar D, Carpenter W, Morihisa JM, King AC, Kessler R, Buchsbaum MS Positron emission tomography in schizophrenic patients with and without neuroleptic medication. J Cereb Blood Flow Metab. 5:1985;201-206.
21. Early TS, Reiman EM, Raichle ME, Spitznagel EL Left globus pallidus abnormality in never-medicated patients with schizophrenia. Proc Natl Acad Sci USA. 84:1987;561-563.
22. Erlenmeyer-Kimling L, Cornblatt B The New York High-Risk Project. A follow up report Schizophr Bull. 13:1987;451-461.
23. Friston KJ, Frith CD Schizophrenia. A disconnection syndrome? Clin Neurosci. 3:1995;89-97.
24. Kane J, Honigfeld G, Singer J, Meltzer H Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatr. 45:1988;789-796.
25. Kay SR, Singh MM Cognitive abnormality in schizophrenia. A dual-process model Biol Psych. 14:1979;155-176.
26. Levy DL Location, location, location. The pathway from behavior to brain locus in schizophrenia Matthysse S, Levy DL, Kagan J, Benes FM Psychopathology. The Evolving Science of Mental Disorder:1996;100-126 Cambridge University Press, Cambridge, UK.
27. Matochik JA, Zametkin AJ, Cohen RM, Hauser P, Weintraub BD Abnormalities in sustained attention and anterior cingulate metabolism in subjects with resistance to thyroid hormone. Br Res. 723:1996;23-28.
28. Matsui T, Hirano A An Atlas of the Human Brain for Computerized Tomograph. 1978;Igaku-Shoin Medical, New York.
29. Mesulam M-M A cortical network for directed attention and unilateral neglect. Ann Neurol. 10:1981;309-325.
30. Nuechterlein KH Vigilance in schizophrenia and related disorders. Steinhauer SR, Gruzelier JH, Zubin J Handbook of Schizophrenia, Vol 5: 1991;397-433 Psychophathology and Information Processing. New York, Neuropsychology. Elsevier Science Publishers B.V.
31. Nuechterlein KH, Buchsbaum MS, Dawson ME Neuropsychological vulnerability to schizophrenia. David AS, Cutting JS The Neuropsychology of Schizophrenia. 1994;Lawrence Erlbaum Assoc, Hillsdale, USA.
32. Overall JE, Gorham DE The brief psychiatric rating scale. Psychol Res. 10:1961;799-812.
33. Phelps ME, Huang S-C, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE Tomographic measurement of local cerebral glucose metabolic rate in humans with [F-18]1-fluro-2-deoxy-D-glucose. Validation of method Ann Neurol. 6:1979;371-388.
34. Pickar D, Owen RR, Litman RE, Konicki PE, Gutierrez R, Rapaport MH Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine Arch Gen Psychiatr. 49:1992;345-353.
35. Posner MI, Petersen SE The attention system of the human brain. Annu Rev Neurosci. 13:1990;25-42.
36. Resnick SM, Gur RE, Alavi A, Gur RC, Reivich M Positron emission tomography and subcortical glucose metabolism in schizophrenia. Psychiatr Res. 24:1988;1-11.
37. Robbins TW The case for fronto-striatal dysfunction in schizophrenia. Schizophr Bull. 16:1990;391-402.
38. Rubin P, Holm S, Friberg L, Videbech P, Andersen HS, Bendsen B, Stromso N, Larsen JK, Lassen N, Hemmingsen R Altered modulation of prefrontal and subcortical brain activity in newly diagnosed schizophrenia and schizophreniform disorder. A regional cerebral blood flow study Arch Gen Psychiatr. 48:1991;987-995.
39. Semple WE, Johnson JL, Cohen R Reliability in positron emission tomography. London ED Imaging Drug Action in the Brain. 1993;297-316 C Press, Boca Raton, CR.
40. Sokoloff L, Reivich M, Kennedy C, DesRosiers MH, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M The [14-C]deoxyglucose method for the determination of local cerebral glucose utilization. Theory, procedure, and normal values in the conscious and anesthetized albino rat J Neurochem. 28:1977;897-916.
41. Tamminga CA, Thaker GK, Buchanan R, Kirkpatrick B, Alphs LD, Chase TN, Carpenter WT Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluordeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatr. 49:1992;522-530.
42. Weinberger DR, Berman KF, Zec RF Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow Arch Gen Psychiatr. 43:1986;114-124.
43. Wolkin A, Jaeger J, Brodie JD, Wolf AP, Fowler J, Retrosen J, Gomez-Mont F, Cancro R Persistence of cerebral metabolic abnormalities in chronic schizophrenia as determined by positron emission tomography. Am J Psychiatr. 142:1985;564-571.
44. Wolkin A, Sanfilipo M, Wolf AP, Angrist B, Brodie J, Rotrosen J Negative symptoms and hypofrontality in chronic schizophrenia. Arch Gen Psychiatr. 49:1992;959-965.